8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
Details for Australian Patent Application No. 2003253418 (hide)
International Classifications
Event Publications
30 October 2003 Complete Application Filed
Priority application(s): 103 12 353.9 20.03.03 DE; 102 38 243.3 21.08.02 DE
22 April 2004 Application Open to Public Inspection
Published as AU-B-2003253418
22 April 2010 Application Accepted
Published as AU-B-2003253418
19 August 2010 Standard Patent Sealed
2 February 2012 Extension of Term of Standard Patents
Boehringer Ingelheim Pharma GmbH & Co. KG The earliest first regulatory approval date provided by the patentee 01 Nov 2011 For the goods TRAJENTA Linagliptin Address for service in Australia: Davies Collison Cave 1 Nicholson Street Melbourne VIC 3000
28 June 2012 Extension granted
Boehringer Ingelheim Pharma GmbH & Co. KG The earliest first regulatory approval date provided by the patentee 01 Nov 2011 For the goods TRAJENTA Linagliptin Extension of Term of patent pursuant to Section 77 expires on 01 Nov 2026
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser